Barclays PLC Legend Biotech Corp Transaction History

Barclays PLC

$327 Billion
Q2 2024

A detailed history of Barclays PLC transactions in Legend Biotech Corp stock. As of the latest transaction made, Barclays PLC holds 196,013 shares of LEGN stock, worth $9.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

196,013

Previous 206,507 5.08%

Holding current value

$9.51 Million

Previous $11.6 Million 25.05%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$39.5 - $57.22 $414,513 - $600,466	-10,494 Reduced 5.08%	196,013 $8.68 Million
Q1 2024 May 15, 2024	BUY	$55.06 - $69.99 $1.05 Million - $1.34 Million	19,122 Added 10.2%	206,507 $11.6 Million
Q4 2023 Feb 15, 2024	SELL	$57.25 - $69.74 $5.36 Million - $6.54 Million	-93,709 Reduced 33.34%	187,385 $11.3 Million
Q3 2023 Nov 07, 2023	BUY	$63.16 - $76.5 $12.5 Million - $15.1 Million	197,357 Added 235.69%	281,094 $18.9 Million
Q2 2023 Aug 03, 2023	SELL	$46.28 - $75.01 $6.47 Million - $10.5 Million	-139,801 Reduced 62.54%	83,737 $5.78 Million
Q1 2023 May 04, 2023	SELL	$43.42 - $57.37 $10.8 Million - $14.3 Million	-248,716 Reduced 52.67%	223,538 $10.8 Million
Q4 2022 Feb 13, 2023	BUY	$38.8 - $55.46 $6.64 Million - $9.49 Million	171,042 Added 56.78%	472,254 $23.6 Million
Q3 2022 Nov 03, 2022	BUY	$38.15 - $57.1 $316,645 - $473,930	8,300 Added 2.83%	301,212 $12.3 Million
Q2 2022 Aug 12, 2022	BUY	$33.54 - $55.0 $1.6 Million - $2.62 Million	47,586 Added 19.4%	292,912 $16.1 Million
Q1 2022 May 16, 2022	BUY	$31.02 - $48.18 $7.61 Million - $11.8 Million	245,326 New	245,326 $8.92 Million

Others Institutions Holding LEGN

# of Institutions

198

Shares Held

74.2M

Call Options Held

374K

Put Options Held

387K

View Full List

About Legend Biotech Corp

Ticker LEGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 167,403,008
Market Cap $8.12B
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...

More about LEGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account